Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
5(83%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_2
2
33%
Ph phase_1
3
50%
Ph phase_3
1
17%

Phase Distribution

3

Early Stage

2

Mid Stage

1

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
3(50.0%)
Phase 2Efficacy & side effects
2(33.3%)
Phase 3Large-scale testing
1(16.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

5

trials recruiting

Total Trials

6

all time

Status Distribution
Active(5)
Completed(1)

Detailed Status

Active, not recruiting3
Recruiting2
Completed1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
5
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 13 (50.0%)
Phase 22 (33.3%)
Phase 31 (16.7%)

Trials by Status

active_not_recruiting350%
completed117%
recruiting233%

Recent Activity

5 active trials
Showing 5 of 6
recruitingphase_2

A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis

NCT07501702
recruitingphase_2

Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)

NCT07204275
active_not_recruitingphase_3

Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)

NCT06564142
active_not_recruitingphase_1

An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases

NCT05732402
completedphase_1

A Study to Evaluate the Relative Bioavailability of Povetacicept Formulations and Bioequivalence of Povetacicept Presentations

NCT07010406
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT07501702Phase 2

A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis

Recruiting
NCT07204275Phase 2

Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)

Recruiting
NCT06564142Phase 3

Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)

Active Not Recruiting
NCT05732402Phase 1

An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases

Active Not Recruiting
NCT07010406Phase 1

A Study to Evaluate the Relative Bioavailability of Povetacicept Formulations and Bioequivalence of Povetacicept Presentations

Completed
NCT05757570Phase 1

An Open-label Study of Povetacicept in Participants With Autoimmune Cytopenias

Active Not Recruiting

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6